

BIOMERICA INC  
Form 8-K  
December 14, 2018

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, DC 20549**

---

**FORM 8-K**  
**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **December 13, 2017**

**BIOMERICA, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**0-8765**  
(Commission  
File Number)

**95-2645573**  
(IRS Employer  
Identification No.)

**17571 Von Karman Ave. Irvine, California**  
(Address of Principal Executive Offices)  
Registrant's telephone number, including area code: **(949) 645-2111**

**92614**  
(Zip Code)

**Not Applicable**

(Former name or former address if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Edgar Filing: BIOMERICA INC - Form 8-K

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---



**Item 5.07 Submission of Matters to a Vote of Security Holders.**

Biomerica, Inc. (the Company) held its 2018 annual meeting (the 2018 Annual Meeting) of stockholders of the Company on December 12, 2018 in Irvine, California. As of October 19, 2018, the record date for the 2018 Annual Meeting, the Company had 8,967,672 shares of its common stock outstanding and entitled to vote, of which 8,070,964 shares of the Company's common stock were present in person or represented by proxy and entitled to vote at the 2018 Annual Meeting. The following is a brief description of the final voting results for each of the proposals submitted to a vote of the stockholders at the 2018 Annual Meeting.

**Proposal No. 1:** The Company's stockholders elected each of the six nominees named below to serve on the Company's Board of Directors until the next annual meeting of stockholders of the Company and until his or her successor has been elected and qualified or until his or her earlier resignation, death or removal.

Nominee	Votes For	Votes Withheld	Broker Non-votes
Zackary Irani	3,339,836	14,827	4,946,515
Janet Moore	3,334,874	19,789	4,946,515
Allen Barbieri	3,340,998	13,665	4,946,515
Francis R. Cano, Ph.D.	3,335,935	18,728	4,946,515
Jane Emerson, M.D., Ph.D.	3,332,910	31,753	4,946,515
Mark Sirgo, Pharm. D.	3,302,036	52,627	4,946,515

**Proposal No. 2:** The Company's stockholders ratified the appointment of PFK, LLP as the Company's independent public accounting firm for the fiscal year ending May 31, 2019.

Votes For	Votes Against	Votes Abstaining	Broker Non-Votes
7,774,960	199,249	96,755	--

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**BIOMERICA, INC.**

Date: December 14, 2018

By:

*/s/ Zackary S. Irani*  
Zackary S. Irani  
Chief Executive Officer